ACRIPTEGA combines three antiretroviral agents:
This triple mechanism provides potent viral suppression and reduces the risk of resistance.
Dolutegravir-based regimens are recommended by WHO as first-line therapy due to their high resistance barrier. Major clinical trials (SINGLE, SPRING-2, FLAMINGO) demonstrated superior and sustained viral suppression compared to alternative regimens.
The combination of tenofovir and lamivudine has long-term evidence supporting durable viral control and immune recovery.
The medication suppresses viral replication and increases CD4 cell count.
Take orally once daily, with or without food, exactly as prescribed by a healthcare provider. Swallow the tablet whole with water. Long-term continuous therapy is usually required.
Contraindications
Side effects









